Drug intelligence / Profile preview

A83-01

Development stage
Preclinical
Lead developer
Node Manabu Laboratory
Modality
Small Molecules
Administration
In Vitro (laboratory Use, Not For Clinical Use), Topical (preclinical Animal Models)
01

Overview

A83-01 is a **potent, selective small molecule inhibitor** of the transforming growth factor-beta (TGF-β) type I receptor kinase (ALK5), activin type IB receptor (ALK4), and nodal type I receptor (ALK7). It blocks TGF-β signaling by inhibiting the phosphorylation of Smad2/3, thereby suppressing downstream effects such as epithelial-to-mesenchymal transition (EMT), apoptosis, and senescence. A83-01 promotes proliferation and maintains the stemness/self-renewal capacity of various cell types in vitro, including human and rat induced pluripotent stem cells and mesenchymal stem cells. It was first described and researched in the context of preventing tumor progression, fibrosis, and enhancing cell culture conditions for stem cell research and regenerative medicine. It is used primarily as a research tool and not as an approved clinical pharmaceutical.

Other names
3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide
02

Targets

TGFBR1ACVR1B (Activin A receptor type IB)

Beyond the preview

Go deeper on A83-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on A83-01.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call